Stocks analysis

ABBV vs ACGL Stock Comparison

Scores Breakdown

Metric ABBV ACGL
📈 Growth 15/30 14/30
💰 Profitability 16/20 16/20
🏦 Financial Health 12/20 19/20
💵 Valuation 12/20 12/20
⚠️ Risk (lower is better) 6/10 3/10
Overall Score 59/100 68/100

Side-by-Side Summaries

ABBV Analysis ACGL Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

Across the 8 most recent quarters (Q1 2026 through Q2 2024), ARCH Capital's revenues edged from about $4.521B to $4.229B, a decline of roughly 6-7%. Net income moved from about $1.047B to $0.988B, a modest downshift. The trajectory shows quarterly fluctuations but an overall stable earnings base, with operating income around $1.1B+ in most periods.

💰 Margins & Cash Flow

Margins hovered in the mid-20% range (roughly 21–26%), and operating margins were similar, signaling disciplined costs and underwriting leverage. Cash flow: operating cash flow was robust in most quarters (e.g., Q1 2026 continuing ops of $1.189B; Q4 2025 around $1.404B), while investing and financing activities were frequently negative, reflecting asset deployment and capital returns. In Q1 2026, net cash flow was -$0.286B due to financing outflows.

🛡️ Balance Sheet & Liquidity

Assets around $81.4B in Q1 2026, with current liabilities around $57.3B; current ratio ~1.4x. Equity near $24.2B and noncurrent liabilities essentially zero, implying strong liquidity and flexibility.

⚠️ Key Drivers & Risks

  • Drivers: Underwriting strength and capital management; steady demand for risk transfer.
  • Risks: Catastrophe exposure and rate sensitivity; interest-rate and valuation sensitivity.